Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study

Telbivudine (LdT) is an orally l-nucleoside with potent and specific antihepatitis B virus (HBV) activity. The higher rate of hepatitis B e antigen (HBeAg) seroconversion of LdT treatment than other anti-HBV agents suggests a potential immunomodulatory effect. The aim of the study was to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiaoling, Li, Jia, Liu, Jie, Gao, Min, Zhou, Li, Lu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466219/
https://www.ncbi.nlm.nih.gov/pubmed/28591041
http://dx.doi.org/10.1097/MD.0000000000007064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466219/
https://www.ncbi.nlm.nih.gov/pubmed/28591041
http://dx.doi.org/10.1097/MD.0000000000007064

Ejemplares similares